{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:36:19Z","timestamp":1761568579440,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.clgc.2014.03.004","type":"journal-article","created":{"date-parts":[[2014,3,19]],"date-time":"2014-03-19T10:08:53Z","timestamp":1395223733000},"page":"312-316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Impact of Enzalutamide Administration on Primary Prostate Cancer Volume: A Metabolic Evaluation by Choline Positron Emission Tomography in Castration-Resistant Prostate Cancer Patients"],"prefix":"10.1016","volume":"12","author":[{"given":"Orazio","family":"Caffo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Maines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Donner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonello","family":"Veccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franca","family":"Chierichetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enzo","family":"Galligioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2014.03.004_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nm972","article-title":"Molecular determinants of resistance to antiandrogen therapy","volume":"10","author":"Chen","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.clgc.2014.03.004_bib2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.clgc.2014.03.004_bib3","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2014.03.004_bib4","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2014.03.004_bib5","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2014.03.004_bib6","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ijrobp.2007.06.050","article-title":"Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02","volume":"70","author":"Lawton","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2014.03.004_bib7","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0360-3016(99)00119-4","article-title":"The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate","volume":"44","author":"Whittington","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2014.03.004_bib8","first-page":"2443","article-title":"Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy","volume":"167","author":"Kucway","year":"2002","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2014.03.004_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.urology.2006.01.061","article-title":"Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy","volume":"68","author":"Merrick","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2014.03.004_bib10","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0936-6555(03)00093-1","article-title":"Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study","volume":"15","author":"Henderson","year":"2003","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.clgc.2014.03.004_bib11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.urolonc.2007.05.014","article-title":"Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity","volume":"26","author":"Petit","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2014.03.004_bib12","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.urology.2007.05.024","article-title":"Surgical and biologic outcomes after\u00a0neoadjuvant bicalutamide treatment in prostate cancer","volume":"70","author":"Gravina","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2014.03.004_bib13","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2014.03.004_bib14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2014.03.004_bib15","article-title":"Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study","volume":"30","author":"Taplin","year":"2012","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.clgc.2014.03.004_bib16","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00259-008-0716-2","article-title":"[(11)C]choline uptake with PET\/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and antiandrogenic therapy","volume":"35","author":"Giovacchini","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767314000536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767314000536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:23:42Z","timestamp":1761564222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767314000536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1558767314000536"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2014.03.004","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Enzalutamide Administration on Primary Prostate Cancer Volume: A Metabolic Evaluation by Choline Positron Emission Tomography in Castration-Resistant Prostate Cancer Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2014.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}